您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > CHIR-99021(CT99021)HCl
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CHIR-99021(CT99021)HCl
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CHIR-99021(CT99021)HCl图片
CAS NO:1797989-42-4
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件

Molecular Weight (MW)

501.8

Formula

C22H18Cl2N8.HCl

CAS No.

1797989-42-4 (HCl);

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 93 mg/mL (185.33 mM)

Water: <1 mg/mL (slightly soluble or insoluble)

Ethanol: <1 mg/mL (slightly soluble or insoluble)

Synonym

CHIR-73911 HCl; CHIR73911; CHIR 73911 hydrochloride ; CHIR-911; CHIR911; CHIR 911; CT- 99021; CT-99021; CT- 99021; GSK 3 inhibitor XVI; GSK 3IXV; CHIR99021; CHIR 99021

实验参考方法

General

Oral administration of CHIR-99021 at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels.

Animal model

Female db/db mice or male ZDF rats with type 2 diabetes

Formulation

Formulated as solutions in 20 mM citrate-buffered 15% Captisol or as fine suspensions in 0.5% carboxymethylcellulose.

Dosages

48 mg/kg

Administration

Oral gavage

Reference

[1] Ring DB, et al. Diabetes, 2003, 52(3), 588-595.

生物活性